TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38198106
Drug: Carglumic acid
Normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carglumic acid treatment for at least 1 year
Study: 38198456
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with placebo
Study: 38199617
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge with one of two strains of non-typhoidal
Study: 38199626
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of prescribing recommendations from the OPTICA medication review
Study: 38199626
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in the number of long-term medications
Study: 38199626
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in medication appropriateness (Medication Appropriateness Index)
Study: 38199634
Drug: HOW R
Normalized name: R-348
DrugBank: R-348 (DB06321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOW R U? weekly volunteer-peer support telephone intervention
Study: 38199634
Drug: HOW R
Normalized name: R-348
DrugBank: R-348 (DB06321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOW R U? delivered using a video-conferencing solution
Study: 38199751
Drug: Target lesion
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target lesion revascularization (TLR) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Study: 38199789
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (two uninterrupted rounds of ovarian stimulation with GnRH agonist triggering)
Study: 38200171
Drug: Microneedling radiofrequency
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling radiofrequency (RF) treatment continued monthly over 6 months after 2 months of conventional therapy.
Study: 38200233
Drug: DFMO (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFMO (up to 9000 mg/m) with celecoxib, cyclophosphamide, and topotecan
Study: 38200320
Drug: Aflibercept 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 0.4 mg/eye
Study: 38200325
Drug: Fentanyl 0.5-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5-1 mcg/kg intravenously
Study: 38200325
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution intravenously
Study: 38203214
Drug: Single-agent regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single-agent regorafenib
Study: 38203593
Drug: AAT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAT treatment
Study: 38204364
Drug: Oral tramadol/dexketoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol/dexketoprofen (TRAM/DKP)
Study: 38204364
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol + tramadol (PARA+TRAM)
Study: 38205679
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of allogeneic adipose-derived mesenchymal stem cells (ADSCs) GXCPC1
Study: 38206151
Drug: PLLA-SCA injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLLA-SCA injections (150 mg; 8 mL reconstitution in sterile water for injection) + 1 mL lidocaine hydrochloride (2%)
Study: 38206151
Drug: PLLA-SCA injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLLA-SCA injections
Study: 38206187
Drug: Doravirine (biological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine (biological cutoff 3.0)
Study: 38206518
Drug: Biosimilars (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosimilars (TNF inhibitors) - adalimumab (ADA), etanercept (ETA), infliximab (IFX)
Study: 38206518
Drug: Biosimilars (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosimilars (TNF inhibitors)
Study: 38206614
Drug: Low-dose cohort
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cohort (4 Gy × 10 fractions + 25 Gy SABR boost, 5 Gy × 5 fractions)
Study: 38206614
Drug: Intermediate-dose cohort
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose cohort (4 Gy × 10 fractions + 30 Gy SABR boost, 6 Gy × 5 fractions)
Study: 38206614
Drug: High-dose cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cohort (4 Gy × 10 fractions + 35 Gy SABR boost, 7 Gy × 5 fractions)
Study: 38206631
Drug: Mirtazapine 15
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 15 mg for 2 weeks followed by 30 mg until week 8
Study: 38206830
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel 120 mg plus Temozolomide (TMZ)
Study: 38206830
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel 120 mg maintenance
Study: 38206830
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (LAN plus TMZ)
Study: 38206930
Drug: Varenicline (0.5‒2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5‒2 mg) and Bupropion SR (150‒300 mg)
Study: 38207208
Drug: mini-hyper-CVD plus
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: mini-hyper-CVD plus venetoclax (200 mg or 400 mg daily)
Study: 38207246
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with proactive symptom assessment (peer volunteer weekly phone calls)
Study: 38211601
Drug: Oral linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral linezolid (600 mg once per day for 5 days)
Study: 38211601
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin G (single dose of 2.4 million international units)
Study: 38211604
Drug: Linaclotide 72
Normalized name: LINACLOTIDE 72MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 72 μg once daily for 12 weeks
Study: 38211606
Drug: Subtyping-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtyping-based therapy (nab-paclitaxel 100 mg/m2 in 28-day cycles)
Study: 38211606
Drug: Subtyping-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtyping-based therapy
Study: 38211725
Drug: CoCM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoCM plus Written Exposure Therapy (CoCM+WET)
Study: 38212127
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of low-dose nivolumab (10 mg, every 2 weeks) plus intratumoral administration of 10 mg ipilimumab and 50 µg AS01
Study: 38212206
Drug: Real-world clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world clinical practice (RWCP) therapy
Study: 38212321
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of DHES0815A
Study: 38212769
Drug: DNTGF-βR armored
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNTGF-βR armored CAR-T cell therapy
Study: 38212823
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy (UT) without BBT
Study: 38212837
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) model called IDoser for FSH dosing
Study: 38212837
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice FSH dosing determined by clinician
Study: 38212847
Drug: Daily yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily yogurt consumption (5 oz) for 8 weeks
Study: 38212851
Drug: Multidimensional individually
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidimensional individually tailored intervention including Norwegian Psychomotor Physiotherapy (NPMP), cognitive behavioural therapy, and a rehabilitation plan
Study: 38212850
Drug: Insulin resistance-related
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance-related features (IR)
Study: 38212850
Drug: Higher triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher triglyceride (TG) and lower estimated insulin sensitivity (eIS)
Study: 38212850
Drug: Estimated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estimated insulin sensitivity (eIS)
Study: 38212853
Drug: Cognitive bias
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive bias modification training (CBMT) - 4-week, 8-session, tablet-delivered intervention
Study: 38213401
Drug: Home-based telerehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based telerehabilitation (tele-physical/occupational therapy)
Study: 38214239
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use ≤7 days of index stroke
Study: 38214239
Drug: Control (non-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-aspirin users)
Study: 38214256
Drug: Ridaforolimus-eluting stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus-eluting stent with shortened dual antiplatelet therapy (DAPT) for 1 month for stable angina or 1 to 3 months for acute coronary syndrome at investigator's discretion.
Study: 38214552
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA (2g) administered 2 hours before surgery and 4 hours after incision
Study: 38214552
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (1g) administered 30 minutes before surgery and 4 hours after incision
Study: 38214552
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA and Intravenous TXA
Study: 38214710
Drug: Shatavari (26,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shatavari (26,500 mg/d fresh weight)
Study: 38214795
Drug: Cysticlean™ 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysticlean™ 240 mg
Study: 38214963
Drug: Rosie chatbot
Normalized name: Rose Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosie chatbot treatment group
Study: 38215127
Drug: Angiopuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiopuncture therapy
Study: 38215770
Drug: De-escalation to
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation to narrower-spectrum antibiotics (ampicillin, trimethoprim-sulfamethoxazole, cefuroxime, cefotaxime, ceftriaxone, amoxicillin-clavulanic acid, ciprofloxacin, or ertapenem)
Study: 38216183
Drug: Monthly quantitative
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly quantitative surveys and daily diaries
Study: 38216189
Drug: AF screening
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF screening enrichment using a risk prediction model (RPM) followed by 14 days of a continuous ECG patch
Study: 38216198
Drug: Interruptive alert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruptive alert for oral fluid restriction in patients treated with intravenous furosemide
Study: 38216200
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (1650 mg daily)
Study: 38216296
Drug: Continuous intrafemoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrafemoral thrombolysis (urokinase injection for 7 days)
Study: 38216511
Drug: Flecainide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (150 mg per day in a single sustained-release dose) for 6 months
Study: 38216511
Drug: Flecainide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (150 mg per day in a single sustained-release dose) for 3 months
Study: 38216511
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (standard of care) for 6 months
Study: 38216554
Drug: Carcinoembryonic antigen-expressing
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA) administered at the resection cavity (Group A)
Study: 38216554
Drug: Carcinoembryonic antigen-expressing
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA) administered intratumorally on day 1, followed by a second dose in the resection cavity on day 5 (Group B)
Study: 38216784
Drug: Gender-affirming hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gender-affirming hormone therapy for trans women
Study: 38216784
Drug: Gender-affirming hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gender-affirming hormone therapy for trans men
Study: 38217032
Drug: Upfront, early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront, early radiotherapy to ≤ 5 high-risk spine lesions plus standard-of-care systemic therapy (20-30 Gy of radiation in 2-10 fractions)
Study: 38217032
Drug: Standard-of-care systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care systemic therapy
Study: 38217039
Drug: Urine osmolality
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine osmolality > 760 mosmol/kg or urine creatinine > 13 mmol/L
Study: 38217039
Drug: Days with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days with urine output < 1 L
Study: 38218194
Drug: Fexinidazole 600
Normalized name: fexinidazole 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexinidazole 600 mg once daily for 10 days (6.0 g total dose)
Study: 38218194
Drug: Fexinidazole 1200
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexinidazole 1200 mg daily for 3 days (3.6 g total)
Study: 38218194
Drug: Fexinidazole 600
Normalized name: fexinidazole 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexinidazole 600 mg daily for 3 days followed by 1200 mg daily for 4 days (6.6 g total)
Study: 38218195
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day for 60 days (low dose group)
Study: 38218195
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day for 15 days (short treatment group)
Study: 38218195
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day for 60 days (control group)
Study: 38218919
Drug: YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: YAG laser vitreolysis (early treatment group)
Study: 38218919
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser treatment (early treatment group)
Study: 38218919
Drug: YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: YAG laser vitreolysis (delayed treatment group)
Study: 38218919
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser treatment (delayed treatment group)
Study: 38218924
Drug: Low-dose quadruple
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose quadruple antihypertensives (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg)
Study: 38218924
Drug: Standard-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose dual antihypertensives (irbesartan 150 mg + amlodipine 5 mg)
Study: 38218936
Drug: telephone-delivered Common
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telephone-delivered Common Elements Treatment Approach (t-CETA)
Study: 38218979
Drug: VT1021 (11.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: VT1021 (11.8 mg/kg, RP2D)
Study: 38219157
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (Group C)
Study: 38220413
Drug: Curcumin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (three capsules of 500 mg of Curcuma longa extract, with 98.42 % total curcuminoids) for twelve weeks
Study: 38220413
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three capsules of 500 mg of starch) for twelve weeks
Study: 38221808
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg hydromorphone (Day 2)
Study: 38221808
Drug: 0 mg,
Normalized name: Winrevair 60 MG, 2 Vial Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg, 2 mg and 8 mg hydromorphone (Days 3-5)
Study: 38222312
Drug: Lymphodepletion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepletion therapy consisting of cyclophosphamide (30mg/kg) for 2 days followed by Fludarabine (25mg/m2) and TILs infusion.
Study: 38224478
Drug: OCH-NCNP1 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCH-NCNP1 (3.0 mg, orally administered once weekly for 24 weeks)
Study: 38224663
Drug: Definitive chemoradiation
Normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definitive chemoradiation with a dose of 50.4 Gy in 28 fractions and a concomitant boost of 62 Gy in 28 fractions to the primary target volume (CTV-/PTV-T)
Study: 38224706
Drug: IPTp with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPTp with dihydroartemisinin-piperaquine plus daily co-trimoxazole
Study: 38224706
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus daily co-trimoxazole
Study: 38224710
Drug: Daily co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine (3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for 3 days)
Study: 38224710
Drug: Daily co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-trimoxazole plus monthly placebo
Study: 38224710
Drug: Daily co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine
Study: 38225549
Drug: nabiximols in
Normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabiximols in combination with TMZ
Study: 38225549
Drug: placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo in combination with TMZ
Study: 38225579
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 17.5 mg weekly by subcutaneous injection for 12 months
Study: 38225598
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral favipiravir (3.6g on day 0 followed by 1.6g daily for 7 days)
Study: 38225598
Drug: No study
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study drug (Control)
Study: 38225650
Drug: Sequential levofloxacin-based
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential levofloxacin-based treatment regimen
Study: 38225650
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (proton-pump inhibitor and amoxicillin)
Study: 38225952
Drug: 300 IR
Normalized name: ORALAIR 300 IR TAB,SL PKT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR HDM SLIT tablet
Study: 38226507
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application with just-in-time adaptive intervention promoting physical activity and lower-sodium food choices, including weekly goal setting.
Study: 38226931
Drug: N-803 plus
Normalized name: (+/-)-N-methylephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-803 plus BCG therapy
Study: 38227033
Drug: Toripalimab +
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab + chemotherapy
Study: 38227308
Drug: MultiStem (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MultiStem (1.2 billion cells, intravenous)
Study: 38227315
Drug: Health literacy-informed
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health literacy-informed discharge medication communication bundle (n=99)
Study: 38227447
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of antihypertensive therapy with maximally tolerated doses of a β-blocker, a long-acting dihydropyridine calcium channel blocker, and a renin-angiotensin system inhibitor.
Study: 38227447
Drug: Adequate time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate time on dialysis of at least 4 hours for delivering an adequate dialysis dose.
Study: 38227933
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A (4000 IU/kg, maximum 250,000 IU)
Study: 38228387
Drug: Combined standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined standard medical treatment (SMT) and endovascular thrombectomy (EVT)
Study: 38229072
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein dose
Study: 38229181
Drug: Transdiagnostic sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic sleep treatment (six sessions)
Study: 38229199
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg octreotide subcutaneous depot (CAM2029) every 2 weeks (Q2W)
Study: 38229199
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of SRL therapy at standard doses (octreotide LAR 30 mg or lanreotide ATG 120 mg every 4 weeks [Q4W])
Study: 38229269
Drug: Damoctocog alfa
Normalized name: DAMOCTOCOG ALFA PEGOL
DrugBank: Damoctocog alfa pegol (DB14700)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Damoctocog alfa pegol (BAY 94-9027, Jivi) at 45 IU/kg every 5 days or 40 IU/kg twice-weekly
Study: 38229356
Drug: Tofacitinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib monotherapy (masked methotrexate withdrawal)